Abstract
Over the past two decades, it has been established that cancer patients with oligometastases, i.e., only a few detectable metastases confined to one or a few organs, may benefit from an aggressive local treatment approach such as the application of high-precision stereotactic body radiotherapy (SBRT). Specifically, some studies have indicated that achieving long-term local tumor control of oligometastases is associated with prolonged overall survival. This motivates investigations into which factors may modify the dose-response relationship of SBRT by making metastases more or less radioresistant. One such factor relates to the uptake of the positron emission tomography tracer 2-deoxy-2-[18F]fluoro-D-glucose (FDG) which reflects the extent of tumor cell glycolysis or the Warburg effect, respectively. Here we review the biological mechanisms how the Warburg effect drives tumor cell radioresistance and metastasis and draw connections to clinical studies reporting associations between high FDG uptake and worse clinical outcomes after SBRT for oligometastases. We further review the evidence for distinct metabolic phenotypes of metastases preferentially seeding to specific organs and their possible translation into distinct radioresistance. Finally, evidence that obesity and hyperglycemia also affect outcomes after SBRT will be presented. While delivered dose is the main determinant of a high local tumor control probability, there might be clinical scenarios when metabolic targeting could make the difference between achieving local control or not, for example when doses have to be compromised in order to spare neighboring high-risk organs, or when tumors are expected to be highly therapy-resistant due to heavy pretreatment such as chemotherapy and/or radiotherapy.
Similar content being viewed by others
Notes
We apply the standard oncological definition of “cure” which is a five-year disease-free interval after therapy.
While SBRT refers to extracranial sites, the analogous, highly conformal radiation technique for treating individual brain tumors is usually called radiosurgery. This will not be the subject of this review.
BED denotes the biologically effective dose which is calculated as \(\textrm{BED}= nd\left(1+\frac{d}{\alpha /\beta}\right)\), with n being the number of fractions, d the single fraction dose and α/β was assumed to be 10 Gy.
References
Dillekås, H., Rogers, M. S., & Straume, O. (2019). Are 90% of deaths from cancer caused by metastases? Cancer Medicine, 8(12), 5574–5576. https://doi.org/10.1002/cam4.2474
Jones, H. B. (1956). Demographic consideration of the cancer problem. Transactions of the New York Academy of Sciences, 18(4), 298–333. https://doi.org/10.1111/j.2164-0947.1956.tb00453.x
Edlich, R. F., Shea, M. A., Foker, J. E., Grondin, C., Castaneda, A. R., & Varco, R. L. (1966). A review of 26 years’ experience with pulmonary resection for metastatic cancer. Diseases of the Chest, 49(6), 587–594. https://doi.org/10.1378/chest.49.6.587
Mountain, C. F., McMurtrey, M. J., & Hermes, K. E. (1984). Surgery for pulmonary metastasis: A 20-year experience. Annals of Thoracic Surgery, 38(4), 323–330. https://doi.org/10.1016/S0003-4975(10)62280-1
Foster, J. H. (1978). Survival after liver resection for secondary tumors. The American Journal of Surgery, 135(3), 389–394. https://doi.org/10.1016/0002-9610(78)90072-7
van Dongen, J. A., & van Slooten, E. A. (1978). The surgical treatment of pulmonary metastases. Cancer Treatment Reviews, 5, 29–48.
Hellman, S., & Weichselbaum, R. R. (1995). Oligometastases. Journal of Clinical Oncology, 13(1), 8–10.
Kendal, W. S. (2014). Oligometastasis as a predictor for occult disease. Mathematical Biosciences, 251(1), 1–10. https://doi.org/10.1016/j.mbs.2014.02.006
Gutiontov, S. I., Pitroda, S. P., Tran, P. T., & Weichselbaum, R. R. (2021). (Oligo)metastasis as a spectrum of disease. Cancer Research, 81(10), 2577–2583. https://doi.org/10.1158/0008-5472.can-20-3337
Tree, A. C., Khoo, V. S., Eeles, R. A., Ahmed, M., Dearnaley, D. P., Hawkins, M. A., Huddart, R. A., Nutting, C. M., Ostler, P. J., & van As, N. J. (2013). Stereotactic body radiotherapy for oligometastases. Lancet Oncology, 14(1), e28–e37. https://doi.org/10.1016/S1470-2045(12)70510-7
Otake, S., & Goto, T. (2019). Stereotactic radiotherapy for oligometastasis. Cancers, 11, 133. https://doi.org/10.3390/cancers11020133
Ruers, T., Van Coevorden, F., Punt, C. J. A., Pierie, J.-P. E. N., Borel-Rinkes, I., Ledermann, J. A., Poston, G., Bechstein, W., Lentz, M.-A., Mauer, M., Folprecht, G., Van Cutsem, E., Ducreux, M., & Nordlinger, B. (2017). Local treatment of unresectable colorectal liver metastases: Results of a randomized phase ii trial. Journal of the National Cancer Institute, 109(9), 1–10. https://doi.org/10.1093/jnci/djx015
Iyengar, P., Kavanagh, B. D., Wardak, Z., Smith, I., Ahn, C., Gerber, D. E., Dowell, J., Hughes, R., Abdulrahman, R., Camidge, D. R., Gaspar, L. E., Doebele, R. C., Bunn, P. A., Choy, H., & Timmerman, R. (2014). Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. Journal of Clinical Oncology, 32(34), 3824–3830. https://doi.org/10.1200/JCO.2014.56.7412
Gomez, D. R., Tang, C., Zhang, J., Blumenschein, G. R., Hernandez, M., Jack Lee, J., Ye, R., Palma, D. A., Louie, A. V., Camidge, D. R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Welsh, J. W., Gibbons, D. L., Karam, J. A., Kavanagh, B. D., Tsao, A. S., Sepesi, B., et al. (2019). Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study. Journal of Clinical Oncology, 37(18), 1558–1565. https://doi.org/10.1200/JCO.19.00201
Palma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., Schellenberg, D., Ahmad, B., Senthi, S., Swaminath, A., Kopek, N., Liu, M., Moore, K., Currie, S., Schlijper, R., et al. (2020). Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET Phase II randomized trial. Journal of Clinical Oncology, 38(25), 2830–2838. https://doi.org/10.1200/JCO.20.00818
MacDermed, D. M., Weichselbaum, R. R., & Salama, J. K. (2008). A rationale for the targeted treatment of oligometastases with radiotherapy. Journal of Surgical Oncology, 98(3), 202–206. https://doi.org/10.1002/jso.21102
Widder, J., Klinkenberg, T. J., Ubbels, J. F., Wiegman, E. M., Groen, H. J. M., & Langendijk, J. A. (2013). Pulmonary oligometastases: Metastasectomy or stereotactic ablative radiotherapy? Radiotherapy and Oncology, 107(3), 409–413. https://doi.org/10.1016/j.radonc.2013.05.024
Lodeweges, J. E., Klinkenberg, T. J., Ubbels, J. F., Groen, H. J. M., Langendijk, J. A., & Widder, J. (2017). Long-term outcome of surgery or stereotactic radiotherapy for lung oligometastases. Journal of Thoracic Oncology, 12(9), 1442–1445. https://doi.org/10.1016/j.jtho.2017.05.015
Phillips, R., Shi, W. Y., Deek, M., Radwan, N., Lim, S. J., Antonarakis, E. S., Rowe, S. P., Ross, A. E., Gorin, M. A., Deville, C., Greco, S. C., Wang, H., Denmeade, S. R., Paller, C. J., Dipasquale, S., DeWeese, T. L., Song, D. Y., Wang, H., Carducci, M. A., et al. (2020). Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncology, 6(5), 650–659. https://doi.org/10.1001/jamaoncol.2020.0147
Klement, R. J., Abbasi-Senger, N., Adebahr, S., Alheid, H., Allgaeuer, M., Becker, G., Blanck, O., Boda-Heggemann, J., Brunner, T., Duma, M., Eble, M. J., Ernst, I., Gerum, S., Habermehl, D., Hass, P., Henkenberens, C., Hildebrandt, G., Imhoff, D., Kahl, H., et al. (2019). The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: A combined analysis of 388 patients with 500 metastases. BMC Cancer, 19, 173. https://doi.org/10.1186/s12885-019-5362-5
Yamamoto, T., Niibe, Y., Aoki, M., Shintani, T., Yamada, K., Kobayashi, M., Yamashita, H., Ozaki, M., Manabe, Y., Onishi, H., Yahara, K., Nishikawa, A., Katsui, K., Oh, R.-J., Terahara, A., & Jingu, K. (2020). Analyses of the local control of pulmonary oligometastases after stereotactic body radiotherapy and the impact of local control on survival. BMC Cancer, 20, 997. https://doi.org/10.1186/s12885-020-07514-9
Takeda, A., Yokosuka, N., Ohashi, T., Kunieda, E., Fujii, H., Aoki, Y., Sanuki, N., Koike, N., & Ozawa, Y. (2011). The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT). Radiotherapy and Oncology, 101(2), 291–297. https://doi.org/10.1016/j.radonc.2011.08.008
Clarke, K., Taremi, M., Dahele, M., Freeman, M., Fung, S., Franks, K., Bezjak, A., Brade, A., Cho, J., Hope, A., & Sun, A. (2012). Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): Is FDG-PET a predictor of outcome? Radiotherapy and Oncology, 104(1), 62–66. https://doi.org/10.1016/j.radonc.2012.04.019
Abelson, J. A., Murphy, J. D., Trakul, N., Bazan, J. G., Maxim, P. G., Graves, E. E., Quon, A., Le, Q.-T., Diehn, M., & Loo, B. W. (2012). Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy. Lung Cancer, 78(3), 219–224. https://doi.org/10.1016/j.lungcan.2012.08.016
Mazzola, R., Fersino, S., Alongi, P., Di Paola, G., Gregucci, F., Aiello, D., Tebano, U., Pasetto, S., Ruggieri, R., Salgarello, M., & Alongi, F. (2018). Stereotactic body radiation therapy for liver oligometastases: Predictive factors of local response by 18F-FDG-PET/CT. British Journal of Radiology, 91(1088), 20180058. https://doi.org/10.1259/bjr.20180058
Oikonomou, A., Khalvati, F., Tyrrell, P. N., Haider, M. A., Tarique, U., Jimenez-Juan, L., Tjong, M. C., Poon, I., Eilaghi, A., Ehrlich, L., & Cheung, P. (2018). Radiomics analysis at PET/CT contributes to prognosis of recurrence and survival in lung cancer treated with stereotactic body radiotherapy. Scientific Reports, 8, 4003. https://doi.org/10.1038/s41598-018-22357-y
Rahmim, A., Bak-Fredslund, K. P., Ashrafinia, S., Lu, L., Schmidtlein, C. R., Subramaniam, R. M., Morsing, A., Keiding, S., Horsager, J., & Munk, O. L. (2019). Prognostic modeling for patients with colorectal liver metastases incorporating FDG PET radiomic features. European Journal of Radiology, 113(February), 101–109. https://doi.org/10.1016/j.ejrad.2019.02.006
Dissaux, G., Visvikis, D., da-ano, R., Pradier, O., Chajon, E., Barillot, I., Duvergé, L., Masson, I., Abgral, R., Santiago Ribeiro, M. J., Devillers, A., Pallardy, A., Fleury, V., Mahé, M. A., de Crevoisier, R., Hatt, M., & Schick, U. (2020). Pretreatment 18F-FDG PET/CT radiomics predict local recurrence in patients treated with stereotactic body radiotherapy for early-stage non-small cell lung cancer: A multicentric study. Journal of Nuclear Medicine, 61(6), 814–820. https://doi.org/10.2967/jnumed.119.228106
Carles, M., Fechter, T., Radicioni, G., Schimek-Jasch, T., Adebahr, S., Zamboglou, C., Nicolay, N. H., Martí-Bonmatí, L., Nestle, U., Grosu, A. L., Baltas, D., Mix, M., & Gkika, E. (2021). FDG-PET radiomics for response monitoring in non-small-cell lung cancer treated with radiation therapy. Cancers, 13(4), 814. https://doi.org/10.3390/cancers13040814
Apostolova, I., Wedel, F., & Brenner, W. (2016). Imaging of tumor metabolism using positron emission tomography (PET). In T. Cramer & C. A. Schmitt (Eds.), Metabolism in Cancer (1st ed., pp. 177–205). Springer International Publishing. https://doi.org/10.1007/978-3-319-42118-6_8
El Naqa, I. (2014). The role of quantitative PET in predicting cancer treatment outcomes. Clinical and Translational Imaging, 2(4), 305–320. https://doi.org/10.1007/s40336-014-0063-1
Warburg, O., Posener, K., & Negelein, E. (1924). Über den Stoffwechsel der Carcinomzelle. Biochemische Zeitschrift, 152, 309–343.
Warburg, O., Wind, F., & Negelein, E. (1926). Über den Stoffwechsel der Tumoren im Körper. Klinische Wochenschrift, 5, 829–838.
Warburg, O., Wind, F., & Negelein, E. (1927). The metabolism of tumors in the body. The Journal of General Physiology, 8(6), 519–530.
Pedersen, P. L. (1978). Tumor mitochondria and the bioenergetics of cancer cells. Progress in Experimental Tumor Research, 22, 190–274. https://doi.org/10.1159/000401202
Carew, J. S., & Huang, P. (2002). Mitochondrial defects in cancer. Molecular Cancer, 1, 9. https://doi.org/10.1186/1476-4598-1-9
Wallace, D. C. (2005). Mitochondria and cancer: Warburg addressed. Cold Spring Harbor Symposia on Quantitative Biology, 70, 363–374. https://doi.org/10.1101/sqb.2005.70.035
Xia, M. F., Zhang, Y. Z., Jin, K., Lu, Z. T., Zeng, Z., & Xiong, W. (2019). Communication between mitochondria and other organelles: A brand-new perspective on mitochondria in cancer. Cell & Bioscience, 9, 27. https://doi.org/10.1186/s13578-019-0289-8
Seyfried, T. N., & Chinopoulos, C. (2021). Can the mitochondrial metabolic theory explain better the origin and management of cancer than can the somatic mutation theory? Metabolites, 11, 572. https://doi.org/10.3390/metabo11090572
Seyfried, T. N., Arismendi-Morillo, G., Mukherjee, P., & Chinopoulos, C. (2020). On the origin of ATP synthesis in cancer. iScience, 23(11), 101761. https://doi.org/10.1016/j.isci.2020.101761
Seyfried, T. N., & Shelton, L. M. (2010). Cancer as a metabolic disease. Nutrition and Metabolism, 7, 7. https://doi.org/10.1186/1743-7075-7-7
Seyfried, T. N. (2015). Cancer as a mitochondrial metabolic disease. Frontiers in Cell and Development Biology, 3, 43. https://doi.org/10.3389/fcell.2015.00043
Kim, J. W., & Dang, C. V. (2006). Cancer’s molecular sweet tooth and the Warburg effect. Cancer Research, 66(18), 8927–8930. https://doi.org/10.1158/0008-5472.CAN-06-1501
Kim, J. W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006). HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metabolism, 3(3), 177–185. https://doi.org/10.1016/j.cmet.2006.02.002
Semenza, G. L. (2010). HIF-1: Upstream and downstream of cancer metabolism. Current Opinion in Genetics and Development, 20(1), 51–56. https://doi.org/10.1016/j.gde.2009.10.009
Courtnay, R., Ngo, D. C., Malik, N., Ververis, K., Tortorella, S. M., & Karagiannis, T. C. (2015). Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. Molecular Biology Reports, 42(4), 841–851. https://doi.org/10.1007/s11033-015-3858-x
Gallagher, E. J., & LeRoith, D. (2011). Minireview: IGF, insulin, and cancer. Endocrinology, 152(7), 2546–2551. https://doi.org/10.1210/en.2011-0231
Klement, R. J., & Fink, M. K. (2016). Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer. Oncogenesis, 5, e193. https://doi.org/10.1038/oncsis.2016.2
Nussinov, R., Wang, G., Tsai, C. J., Jang, H., Lu, S., Banerjee, A., Zhang, J., & Gaponenko, V. (2017). Calmodulin and PI3K signaling in KRAS cancers. Trends in Cancer, 3(3), 214–224. https://doi.org/10.1016/j.trecan.2017.01.007
Klement, R. J. (2019). The influence of ketogenic therapy on the 5 R’s of radiobiology. International Journal of Radiation Biology, 95(4), 394–407. https://doi.org/10.1080/09553002.2017.1380330
Meister, A. (1983). Selective modification of glutathione metabolism. Science, 220(4596), 472–477.
Sattler, U. G., & Mueller-Klieser, W. (2009). The anti-oxidant capacity of tumour glycolysis. International Journal of Radiation Biology, 85(11), 963–971. https://doi.org/10.3109/09553000903258889
Meijer, T. W. H., Kaanders, J. H. A. M., Span, P. N., & Bussink, J. (2012). Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clinical Cancer Research, 18(20), 5585–5594. https://doi.org/10.1158/1078-0432.CCR-12-0858
Quennet, V., Yaromina, A., Zips, D., Rosner, A., Walenta, S., Baumann, M., & Mueller-klieser, W. (2006). Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiotherapy and Oncology, 81(2), 130–135. https://doi.org/10.1016/j.radonc.2006.08.012
Sattler, U. G. A., Meyer, S. S., Quennet, V., Hoerner, C., Knoerzer, H., Fabian, C., Yaromina, A., Zips, D., Walenta, S., Baumann, M., & Mueller-Klieser, W. (2010). Glycolytic metabolism and tumour response to fractionated irradiation. Radiotherapy and Oncology, 94(1), 102–109. https://doi.org/10.1016/j.radonc.2009.11.007
Mailloux, R. J., & Harper, M.-E. (2011). Uncoupling proteins and the control of mitochondrial reactive oxygen species production. Free Radical Biology & Medicine, 51(6), 1106–1115. https://doi.org/10.1016/j.freeradbiomed.2011.06.022
Vozza, A., Parisi, G., de Leonardis, F., Lasorsa, F. M., Castegna, A., Amorese, D., Marmo, R., Calcagnile, V. M., Palmieri, L., Ricquier, D., Paradies, E., Scarcia, P., Palmieri, F., Bouillaud, F., & Fiermonte, G. (2014). UCP2 transports C4 metabolites out of mitochondria, regulating glucose and glutamine oxidation. Proceedings of the National Academy of Sciences, 111(3), 960–965. https://doi.org/10.1073/pnas.1317400111
Lemos, D., Oliveira, T., Martins, L., de Azevedo, V. R., Rodrigues, M. F., Ketzer, L. A., & Rumjanek, F. D. (2019). Isothermal microcalorimetry of tumor cells: Enhanced thermogenesis by metastatic cells. Frontiers in Oncology, 9, 1430. https://doi.org/10.3389/fonc.2019.01430
Liu, C. H., Huang, Z. H., Dong, X. Y., Zhang, X. Q., Li, Y. H., Zhao, G., Sun, B. S., & Shen, Y. N. (2020). Inhibition of uncoupling protein 2 enhances the radiosensitivity of cervical cancer cells by promoting the production of reactive oxygen species. Oxidative Medicine and Cellular Longevity, 2020, 5135893. https://doi.org/10.1155/2020/5135893
Sun, A., Johansson, S., Turesson, I., Dau, A., & Sörensen, J. (2012). Imaging tumor perfusion and oxidative metabolism in patients with head-and-neck cancer using 1- [ 11C]-acetate PET during radiotherapy: Preliminary results. International Journal of Radiation Oncology Biology Physics, 82(2), 554–560. https://doi.org/10.1016/j.ijrobp.2010.11.007
Dong, M., Liu, J., Sun, X., & Xing, L. (2017). Prognositc significance of SUVmax on pretreatment 18F-FDG PET/CT in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy: A meta-analysis. Journal of Medical Imaging and Radiation Oncology, 61(5), 652–659. https://doi.org/10.1111/1754-9485.12599
Dosani, M., Yang, R., McLay, M., Wilson, D., Liu, M., Yong-Hing, C. J., Hamm, J., Lund, C. R., Olson, R., & Schellenberg, D. (2019). Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy. Current Oncology, 26(1), e57–e63. https://doi.org/10.3747/co.26.4167
Lu, J., Tan, M., & Cai, Q. (2015). The Warburg effect in tumor progression: Mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Letters, 356(2), 156–164. https://doi.org/10.1016/j.canlet.2014.04.001
Payen, V. L., Porporato, P. E., Baselet, B., & Sonveaux, P. (2016). Metabolic changes associated with tumor metastasis, part 1: Tumor pH, glycolysis and the pentose phosphate pathway. Cellular and Molecular Life Sciences, 73(7), 1333–1348. https://doi.org/10.1007/s00018-015-2098-5
Lu, J. (2019). The Warburg metabolism fuels tumor metastasis. Cancer and Metastasis Reviews, 38(1–2), 157–164. https://doi.org/10.1007/s10555-019-09794-5
Huysentruyt, L. C., & Seyfried, T. N. (2010). Perspectives on the mesenchymal origin of metastatic cancer. Cancer and Metastasis Reviews, 29(4), 695–707. https://doi.org/10.1007/s10555-010-9254-z
Seyfried, T. N., & Huysentruyt, L. C. (2013). On the origin of cancer metastasis. Critical Reviews in Oncogenesis, 18(1–2), 43–73. https://doi.org/10.1615/CritRevOncog.v18.i1-2.40
Guerra, F., Guaragnella, N., Arbini, A. A., Bucci, C., Giannattasio, S., & Moro, L. (2017). Mitochondrial dysfunction: A novel potential driver of epithelial-to-mesenchymal transition in cancer. Frontiers in Oncology, 7, 295. https://doi.org/10.3389/fonc.2017.00295
Gatenby, R. A., Smallbone, K., Maini, P. K., Rose, F., Averill, J., Nagle, R. B., Worrall, L., & Gillies, R. J. (2007). Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. British Journal of Cancer, 97(5), 646–653. https://doi.org/10.1038/sj.bjc.6603922
Chen, K. H., Tung, P. Y., Wu, J. C., Chen, Y., Chen, P. C., Huang, S. H., & Wang, S. M. (2008). An acidic extracellular pH induces Src kinase-dependent loss of β-catenin from the adherens junction. Cancer Letters, 267(1), 37–48. https://doi.org/10.1016/j.canlet.2008.03.005
Rozhin, J., Sameni, M., Ziegler, G., & Sloane, B. F. (1994). Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Research, 54(24), 6517–6525.
Bourguignon, L. Y. W., Singleton, P. A., Diedrich, F., Stern, R., & Gilad, E. (2004). CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. Journal of Biological Chemistry, 279(26), 26991–27007. https://doi.org/10.1074/jbc.M311838200
Li, X., Yu, X., Dai, D., Song, X., & Xu, W. (2016). The altered glucose metabolism in tumor and a tumor acidic microenvironment associated with extracellular matrix metalloproteinase inducer and monocarboxylate transporters. Oncotarget, 7(17), 23141–23155. https://doi.org/10.18632/oncotarget.8153
Kato, Y., Lambert, C. A., Colige, A. C., Mineur, P., Noël, A., Frankenne, F., Foidart, J. M., Baba, M., Hata, R. I., Miyazaki, K., & Tsukuda, M. (2005). Acidic extracellular pH induces matrix metalloproteinase-9 expression in mouse metastatic melanoma cells through the phospholipase D-mitogen-activated protein kinase signaling. Journal of Biological Chemistry, 280(12), 10938–10944. https://doi.org/10.1074/jbc.M411313200
Lin, S., Sun, L., Lyu, X., Ai, X., du, D., Su, N., Li, H., Zhang, L., Yu, J., & Yuan, S. (2017). Lactate-activated macrophages induced aerobic glycolysis and epithelial-mesenchymal transition in breast cancer by regulation of CCL5-CCR5 axis: A positive metabolic feedback loop. Oncotarget, 8(66), 110426–110443. https://doi.org/10.18632/oncotarget.22786
Miranda-Gonçalves, V., Lameirinhas, A., Macedo-Silva, C., Lobo, J., C. Dias, P., Ferreira, V., Henrique, R., & Jerónimo, C. (2020). Lactate increases renal cell carcinoma aggressiveness through sirtuin 1-dependent epithelial mesenchymal transition axis regulation. Cells, 9(4), 1053. https://doi.org/10.3390/cells9041053
Stern, R., Shuster, S., Neudecker, B. A., & Formby, B. (2002). Lactate stimulates fibroblast expression of hyaluronan and CD44: The Warburg effect revisited. Experimental Cell Research, 276(1), 24–31. https://doi.org/10.1006/excr.2002.5508
Sullivan, W. J., Mullen, P. J., Schmid, E. W., Flores, A., Momcilovic, M., Sharpley, M. S., Jelinek, D., Whiteley, A. E., Maxwell, M. B., Wilde, B. R., Banerjee, U., Coller, H. A., Shackelford, D. B., Braas, D., Ayer, D. E., de Aguiar Vallim, T. Q., Lowry, W. E., & Christofk, H. R. (2018). Extracellular matrix remodeling regulates glucose metabolism through TXNIP destabilization. Cell, 175(1), 117–132.e21. https://doi.org/10.1016/j.cell.2018.08.017
Walenta, S., Wetterling, M., Lehrke, M., Schwickert, G., Sundfør, K., Rofstad, E. K., & Mueller-Klieser, W. (2000). High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Research, 60(4), 916–921.
Walenta, S., Salameh, A., Lyng, H., Evensen, J. F., Mitze, M., Rofstad, E. K., & Mueller-Klieser, W. (1997). Correlation of high lactate levels in head and neck tumors with incidence of metastasis. The American Journal of Pathology, 150(2), 409–415.
Brizel, D. M., Schroeder, T., Scher, R. L., Walenta, S., Clough, R. W., Dewhirst, M. W., & Mueller-Klieser, W. (2001). Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. International Journal of Radiation Oncology, Biology, Physics, 51(2), 349–353.
Walenta, S., Van Chau, T., Schroeder, T., Lehr, H. A., Kunz-Schughart, L. A., Fuerst, A., & Mueller-Klieser, W. (2003). Metabolic classification of human rectal adenocarcinomas: A novel guideline for clinical oncologists? Journal of Cancer Research and Clinical Oncology, 129(6), 321–326. https://doi.org/10.1007/s00432-003-0450-x
Dupuy, F., Tabariès, S., Andrzejewski, S., Dong, Z., Blagih, J., Annis, M. G., Omeroglu, A., Gao, D., Leung, S., Amir, E., Clemons, M., Aguilar-Mahecha, A., Basik, M., Vincent, E. E., St.-Pierre, J., Jones, R. G., & Siegel, P. M. (2015). PDK1-dependent metabolic reprogramming dictates metastatic potential in breast cancer. Cell Metabolism, 22(4), 577–589. https://doi.org/10.1016/j.cmet.2015.08.007
Montero-Calle, A., Gómez de Cedrón, M., Quijada-Freire, A., Solís-Fernández, G., López-Alonso, V., Espinosa-Salinas, I., Peláez-García, A., Fernández-Aceñero, M. J., Ramírez de Molina, A., & Barderas, R. (2022). Metabolic reprogramming helps to define different metastatic tropisms in colorectal cancer. Frontiers in Oncology, 12, 903033. https://doi.org/10.3389/fonc.2022.903033
Jekabsons, M. B., Merrell, M., Skubiz, A. G., Thornton, N., Milasta, S., Green, D., Chen, T., Wang, Y. H., Avula, B., Khan, I. A., & Zhou, Y. D. (2023). Breast cancer cells that preferentially metastasize to lung or bone are more glycolytic, synthesize serine at greater rates, and consume less ATP and NADPH than parent MDA-MB-231 cells. Cancer & Metabolism, 11, 4. https://doi.org/10.1186/s40170-023-00303-5
Kamarajugadda, S., Stemboroski, L., Cai, Q., Simpson, N. E., Nayak, S., Tan, M., & Lu, J. (2012). Glucose oxidation modulates anoikis and tumor metastasis. Molecular and Cellular Biology, 32(10), 1893–1907. https://doi.org/10.1128/mcb.06248-11
Kim, N. H., Cha, Y. H., Lee, J., Lee, S. H., Yang, J. H., Yun, J. S., Cho, E. S., Zhang, X., Nam, M., Kim, N., Yuk, Y. S., Cha, S. Y., Lee, Y., Ryu, J. K., Park, S., Cheong, J. H., Kang, S. W., Kim, S. Y., Hwang, G. S., et al. (2017). Snail reprograms glucose metabolism by repressing phosphofructokinase PFKP allowing cancer cell survival under metabolic stress. Nature Communications, 8, 4374. https://doi.org/10.1038/ncomms14374
Lee, S. Y., Jeon, H. M., Ju, M. K., Kim, C. H., Yoon, G., Han, S. I., Park, H. G., & Kang, H. S. (2012). Wnt/snail signaling regulates cytochrome c oxidase and glucose metabolism. Cancer Research, 72(14), 3607–3617. https://doi.org/10.1158/0008-5472.CAN-12-0006
Wang, P., Valentijn, A. J., Gilmore, A. P., & Streuli, C. H. (2003). Early events in the anoikis program occur in the absence of caspase activation. Journal of Biological Chemistry, 278(22), 19917–19925. https://doi.org/10.1074/jbc.M210337200
Røsland, G. V., Dyrstad, S. E., Tusubira, D., Helwa, R., Tan, T. Z., Lotsberg, M. L., Pettersen, I. K. N., Berg, A., Kindt, C., Hoel, F., Jacobsen, K., Arason, A. J., Engelsen, A. S. T., Ditzel, H. J., Lønning, P. E., Krakstad, C., Thiery, J. P., Lorens, J. B., Knappskog, S., & Tronstad, K. J. (2019). Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. Cancer & Metabolism, 7, 6. https://doi.org/10.1186/s40170-019-0197-8
Avella, D., Manjunath, Y., Singh, A., Deroche, C. B., Kimchi, E. T., Staveley-O’Carroll, K. F., Mitchem, J. B., Kwon, E., Li, G., & Kaifi, J. T. (2020) 18F-FDG PET/CT total lesion glycolysis is associated with circulating tumor cell counts in patients with stage I to IIIA non-small cell lung cancer. Translational Lung Cancer Research, 9(3), 515–521. https://doi.org/10.21037/tlcr.2020.04.10
Minn, A. J., & Massagué, J. (2011). Invasion and Metastasis. In V. T. DeVita Jr., T. S. Lawrence, & S. A. Rosenberg (Eds.), Primer of the Molecular Biology of Cancer (1st ed., pp. 143–162). Lippincott Wiliams & Wilkins.
Epstein, T., Gatenby, R. A., & Brown, J. S. (2017). The Warburg effect as an adaptation of cancer cells to rapid fluctuations in energy demand. PLoS One, 12(9), e0185085. https://doi.org/10.1371/journal.pone.0185085
Chen, J., Cao, S., Situ, B., Zhong, J., Hu, Y., Li, S., Huang, J., Xu, J., Wu, S., Lin, J., Zhao, Q., Cai, Z., Zheng, L., & Wang, Q. (2018). Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer. Journal of Experimental & Clinical Cancer Research, 37(1), 127. https://doi.org/10.1186/s13046-018-0789-0
Schild, T., Low, V., Blenis, J., & Gomes, A. P. (2018). Unique metabolic adaptations dictate distal organ-specific metastatic colonization. Cancer Cell, 33(3), 347–354. https://doi.org/10.1016/j.ccell.2018.02.001
Ortiz-Prado, E., Dunn, J. F., Vasconez, J., Castillo, D., & Viscor, G. (2019). Partial pressure of oxygen in the human body: a general review. American Journal of Blood Research, 9(1), 1–14.
Stresing, V., Baltziskueta, E., Rubio, N., Blanco, J., Arriba, M., Valls, J., Janier, M., Clézardin, P., Sanz-Pamplona, R., Nieva, C., Marro, M., Dmitri, P., & Sierra, A. (2013). Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs. Oncogene, 32(6), 724–735. https://doi.org/10.1038/onc.2012.93
Cejas, P., López-Gómez, M., Aguayo, C., Madero, R., de Castro Carpeño, J., Belda-Iniesta, C., Barriuso, J., Moreno García, V., Larrauri, J., López, R., Casado, E., Gonzalez-Barón, M., & Feliu, J. (2009). KRAS mutations in primary colorectal cancer tumors and related metastases: A potential role in prediction of lung metastasis. PLoS One, 4(12), e8199. https://doi.org/10.1371/journal.pone.0008199
Tie, J., Lipton, L., Desai, J., Gibbs, P., Jorissen, R. N., Christie, M., Drummond, K. J., Thomson, B. N. J., Usatoff, V., Evans, P. M., Pick, A. W., Knight, S., Carne, P. W. G., Berry, R., Polglase, A., McMurrick, P., Zhao, Q., Busam, D., Strausberg, R. L., et al. (2011). KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clinical Cancer Research, 17(5), 1122–1130. https://doi.org/10.1158/1078-0432.CCR-10-1720
Wang, Z., Zheng, X., Wang, X., Chen, Y., Li, Z., Yu, J., Yang, W., Mao, B., Zhang, H., Li, J., & Shen, L. (2021). Genetic differences between lung metastases and liver metastases from left-sided microsatellite stable colorectal cancer: Next generation sequencing and clinical implications. Annals of Translational Medicine, 9(12), 967–967. https://doi.org/10.21037/atm-21-2221
Yang, L., Shen, C., Estrada-Bernal, A., Robb, R., Chatterjee, M., Sebastian, N., Webb, A., Mo, X., Chen, W., Krishnan, S., & Williams, T. M. (2021). Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair. Nucleic Acids Research, 49(19), 11067–11082. https://doi.org/10.1093/nar/gkab871
Mazzola, R., Fiorentino, A., di Paola, G., Giaj Levra, N., Ricchetti, F., Fersino, S., Tebano, U., Pasetto, S., Ruggieri, R., Salgarello, M., & Alongi, F. (2017). Stereotactic ablative radiation therapy for lung oligometastases: Predictive parameters of early response by 18FDG-PET/CT. Journal of Thoracic Oncology, 12(3), 547–555. https://doi.org/10.1016/j.jtho.2016.11.2234
Chin, A. L., Kumar, K. A., Guo, H. H., Maxim, P. G., Wakelee, H., Neal, J. W., Diehn, M., Loo, B. W., Jr., & Gensheimer, M. F. (2018). Prognostic value of pretreatment FDG-PET parameters in high-dose image-guided radiotherapy for oligometastatic non–small-cell lung cancer. Clinical Lung Cancer, 19(5), e581–e588. https://doi.org/10.1016/j.cllc.2018.04.003
Greco, C., Pares, O., Pimentel, N., Louro, V., Morales, J., Nunes, B., Castanheira, J., Oliveira, C., Silva, A., Vaz, S., Costa, D., Zelefsky, M., Kolesnick, R., & Fuks, Z. (2019). Phenotype-oriented ablation of oligometastatic cancer with single dose radiation therapy. International Journal of Radiation Oncology Biology Physics, 104(3), 593–603. https://doi.org/10.1016/j.ijrobp.2019.02.033
Wulf, J., Guckenberger, M., Haedinger, U., Oppitz, U., Mueller, G., Baier, K., & Flentje, M. (2006). Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncologica, 45(7), 838–847. https://doi.org/10.1080/02841860600904821
Stintzing, S., Hoffmann, R.-T., Heinemann, V., Kufeld, M., Rentsch, M., & Muacevic, A. (2010). Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumors. Annals of Surgical Oncology, 17(11), 2877–2883. https://doi.org/10.1245/s10434-010-1187-9
Takeda, A., Kunieda, E., Ohashi, T., Aoki, Y., Koike, N., & Takeda, T. (2011). Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiotherapy and Oncology, 101(2), 255–259. https://doi.org/10.1016/j.radonc.2011.05.033
Singh, D., Chen, Y., Hare, M. Z., Usuki, K. Y., Zhang, H., Lundquist, T., Joyce, N., Schell, M. C., & Milano, M. T. (2014). Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. Journal of Thoracic Disease, 6(4), 369–374. https://doi.org/10.3978/j.issn.2072-1439.2013.12.03
Thibault, I., Poon, I., Yeung, L., Erler, D., Kim, A., Keller, B., Lochray, F., Jain, S., Soliman, H., & Cheung, P. (2014). Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: A single institution’s comprehensive experience. Clinical Oncology (Royal College of Radiologists), 26(11), 713–719. https://doi.org/10.1016/j.clon.2014.06.018
Andratschke, N., Parys, A., Stadtfeld, S., Wurster, S., Huttenlocher, S., Imhoff, D., Yildirim, M., Rades, D., Rödel, C. M., Dunst, J., Hildebrandt, G., & Blanck, O. (2016). Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases. Radiation Oncology, 11, 74. https://doi.org/10.1186/s13014-016-0652-4
Aoki, M., Hatayama, Y., Kawaguchi, H., Hirose, K., Sato, M., Akimoto, H., Miura, H., Ono, S., & Takai, Y. (2016). Stereotactic body radiotherapy for lung metastases as oligo-recurrence : A single institutional study. Journal of Radiation Research, 57(1), 55–61. https://doi.org/10.1093/jrr/rrv063
Binkley, M. S., Trakul, N., Jacobs, L. R., von Eyben, R., le, Q. T., Maxim, P. G., Loo, B. W., Jr., Shultz, D. B., & Diehn, M. (2015). Colorectal histology is associated with an increased risk of local failure in lung metastases treated with stereotactic ablative radiation therapy. International Journal of Radiation Oncology Biology Physics, 92(5), 1044–1052. https://doi.org/10.1016/j.ijrobp.2015.04.004
Klement, R. J. (2017). Radiobiological parameters of liver and lung metastases derived from tumor control data of 3719 metastases. Radiotherapy and Oncology, 123(2), 218–226. https://doi.org/10.1016/j.radonc.2017.03.014
Osti, M. F., Agolli, L., Valeriani, M., Reverberi, C., Bracci, S., Marinelli, L., de Sanctis, V., Cortesi, E., Martelli, M., de Dominicis, C., Minniti, G., & Nicosia, L. (2018). 30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease. Lung Cancer, 122(3), 165–170. https://doi.org/10.1016/j.lungcan.2018.06.018
Guckenberger, M., Wulf, J., Mueller, G., Krieger, T., Baier, K., Gabor, M., Richter, A., Wilbert, J., & Flentje, M. (2009). Dose–Response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: Relevance of 4D dose calculation. International Journal of Radiation Oncology, Biology, Physics, 74(1), 47–54. https://doi.org/10.1016/j.ijrobp.2008.06.1939
Filippi, A. R., Badellino, S., Ceccarelli, M., Guarneri, A., Franco, P., Monagheddu, C., Spadi, R., Ragona, R., Racca, P., & Ricardi, U. (2015). Stereotactic ablative radiation therapy as first local therapy for lung oligometastases from colorectal cancer: A single-institution cohort study. International Journal of Radiation Oncology, Biology, Physics, 91(3), 524–529. https://doi.org/10.1016/j.ijrobp.2014.10.046
Fode, M. M., & Høyer, M. (2015). Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. Radiotherapy and Oncology, 114(2), 155–160. https://doi.org/10.1016/j.radonc.2014.12.003
Kim, H. S., Heo, J. S., Lee, J., Lee, J. Y., Lee, M. Y., Lim, S. H., Lee, W. Y., Kim, S. H., Park, Y. A., Cho, Y. B., Yun, S. H., Kim, S. T., Park, J. O., Lim, H. Y., Choi, Y. S., Kwon, W. I., Kim, H. C., & Park, Y. S. (2016). The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: A retrospective analysis. BMC Cancer, 16, 120. https://doi.org/10.1186/s12885-016-2141-4
Sánchez-Muñoz, A., Gallego, E., de Luque, V., Pérez-Rivas, L. G., Vicioso, L., Ribelles, N., Lozano, J., & Alba, E. (2010). Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer, 10, 136. https://doi.org/10.1186/1471-2407-10-136
Milano, M. T., Katz, A. W., Zhang, H., & Okunieff, P. (2012). Oligometastases treated with stereotactic body radiotherapy: Long-term follow-up of prospective study. International Journal of Radiation Oncology, Biology, Physics, 83(3), 878–886. https://doi.org/10.1016/j.ijrobp.2011.08.036
Klement, R. J., Guckenberger, M., Alheid, H., Allgäuer, M., Becker, G., Blanck, O., Boda-Heggemann, J., Brunner, T., Duma, M., Gerum, S., Habermehl, D., Hildebrandt, G., Lewitzki, V., Ostheimer, C., Papachristofilou, A., Petersen, C., Schneider, T., Semrau, R., Wachter, S., & Andratschke, N. (2017). Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control. Radiotherapy and Oncology, 123(2), 227–233. https://doi.org/10.1016/j.radonc.2017.01.013
Klement, R. J., & Champ, C. E. (2014). Calories, carbohydrates, and cancer therapy with radiation: Exploiting the five R’s through dietary manipulation. Cancer and Metastasis Reviews, 33(1), 217–229. https://doi.org/10.1007/s10555-014-9495-3
Klement, R. J., & Champ, C. E. (2017). Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels. Brain, 140(1–2), e16. https://doi.org/10.1093/brain/aww324
Barua, R., Templeton, A. J., Seruga, B., Ocana, A., Amir, E., & Ethier, J. L. (2018). Hyperglycaemia and survival in solid tumours: A systematic review and meta-analysis. Clinical Oncology, 30(4), 215–224. https://doi.org/10.1016/j.clon.2018.01.003
Montemurro, N., Perrini, P., & Rapone, B. (2020). Clinical risk and overall survival in patients with diabetes mellitus, hyperglycemia and glioblastoma multiforme. A review of the current literature. International Journal of Environmental Research and Public Health, 17, 8501.
Huang, Y. J., Chen, Y. T., Huang, C. M., Kuo, S. H., Liao, Y. Y., Jhang, W. Y., Wang, S. H., Ke, C. C., Huang, Y. H., Cheng, C. M., Huang, M. Y., & Chuang, C. H. (2022). HIF-1α expression increases preoperative concurrent chemoradiotherapy resistance in hyperglycemic rectal cancer. Cancers, 14(16), 4053. https://doi.org/10.3390/cancers14164053
Klement, R. J., Koebrunner, P. S., Meyer, D., Kanzler, S., & Sweeney, R. A. (2021). Impact of a ketogenic diet intervention during radiotherapy on body composition: IV. Final results of the KETOCOMP study for rectal cancer patients. Clinical Nutrition, 40, 4674–4684. https://doi.org/10.1016/j.clnu.2021.05.015
Allen, B. G., Bhatia, S. K., Buatti, J. M., Brandt, K. E., Lindholm, K. E., Button, A. M., Szweda, L. I., Smith, B. J., Spitz, D. R., & Fath, M. A. (2013). Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts. Clinical Cancer Research, 19(14), 3905–3913. https://doi.org/10.1158/1078-0432.CCR-12-0287
Kalman, N. S., Hugo, G. D., Mahon, R. N., Deng, X., Mukhopadhyay, N. D., & Weiss, E. (2018). Diabetes mellitus and radiation induced lung injury after thoracic stereotactic body radiotherapy. Radiotherapy and Oncology, 129(2), 270–276. https://doi.org/10.1016/j.radonc.2018.08.024
Huang, X. F., & Chen, J. Z. (2009). Obesity, the PI3K/Akt signal pathway and colon cancer. Obesity Reviews, 10(6), 610–616. https://doi.org/10.1111/j.1467-789X.2009.00607.x
Su, Y.-H., Wu, Y.-Z., Ann, D. K., Chen, J. L.-Y., & Kuo, C.-Y. (2023). Obesity promotes radioresistance through SERPINE1-mediated aggressiveness and DNA repair of triple-negative breast cancer. Cell Death & Disease, 14, 53. https://doi.org/10.1038/s41419-023-05576-8
Park, J. M., Spielman, D. M., Josan, S., Jang, T., Merchant, M., Hurd, R. E., Mayer, D., & Recht, L. D. (2016). Hyperpolarized 13C-lactate to 13C-bicarbonate ratio as a biomarker for monitoring the acute response of anti-vascular endothelial growth factor (anti-VEGF) treatment. NMR in Biomedicine, 29(5), 650–659. https://doi.org/10.1002/nbm.3509
Acknowledgements
This paper was motivated by the topic of a brief talk held by the Rainer J. Klement to obtain his habilitation from the Faculty of Medicine at the University of Zurich, Switzerland.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
RAS and RJK have received travel/accommodation fees for consultant meetings/conferences from Elekta.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Klement, R.J., Sweeney, R.A. Metabolic factors associated with the prognosis of oligometastatic patients treated with stereotactic body radiotherapy. Cancer Metastasis Rev 42, 927–940 (2023). https://doi.org/10.1007/s10555-023-10110-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10555-023-10110-5